Another important contributor to the observed improvement in steatosis is the reduction in plasma insulin which decreases de novo lipogenesis by lowering sterol regulatory element-binding protein 1 (SREBP-1) activity (127) and increases beta-oxidation (59, 86, 87). The gene discussed is SREBF1; the disease is steatosis.